Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Allogeneic hematopoietic stem cell transplantation outcomes in pediatric acute lymphoblastic leukemia: A multicenter analysis from the cccg-ALL-2015 protocol

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXiaohang HuangYZYiping ZhuJPJing Pan

Discussion

Loading...

Member takes

Overview

Multicenter analysis identifies key factors influencing transplant outcomes in pediatric acute lymphoblastic leukemia.

Key Points

  • HSCT improved 5-year overall survival among high-risk pediatric ALL patients compared to chemotherapy.
  • Among patients with non-remission or partial remission, 5-year overall survival reached 47.6% after HSCT.
  • Survival analyses utilized Kaplan-Meier methodology and Cox proportional hazards modeling.
  • Mild chronic graft-versus-host disease contributes to better outcomes, suggesting need for refined transplantation criteria.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e430https://doi.org/10.1182/blood-2025-6074
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia2025
  2. 2Outcomes of pediatric patients transplanted for B-ALL with high-risk cytogenetics- a 20-year experience from LMIC setting2025
  3. 3Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study.2025 · 1 citations
  4. 4Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol2025
  5. 5Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025